A Phase 2/3 interventional study of COMP360 psilocybin in PTSD - Post Traumatic Stress Disorder, PTSD and PTSD Symptoms, sponsored by COMPASS Pathways. Recruiting at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by COMPASS Pathways · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 114 studies in Combat Disorders with a site in United States — 41 open to participants now, 44 under way, 2 of them phase 3. Combat Disorders · United States.
Among the 114 studies in Combat Disorders with a site in United States, this one is the 10th largest by planned enrollment of the 100 interventional ones that give a count, is one of 22 that started in 2026, is one of 3 in phase 2/3, reaches primary completion later than 28 of the 43 other live ones, and was the 101st registered.
203 studies on the registry are indexed under Combat Disorders; 92 are open to participants now.
Browse Combat Disorders studies →41 of the 114 studies in Combat Disorders with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–55
Summit Hyperbarics and Wellness · Sites in United States
Ages 18–75
The University of Texas Health Science Center at San Antonio · Sites in United States
Healthy volunteers
Cognitive FX · Sites in United States
Ages 18–65
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 52 Combat Disorders studies recruiting now, 21 (40%) set no upper age limit and 26 (50%) stop at 75 or younger; 10 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
114 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 16 · Phase 3 5 · Phase 4 3
First in 2004; this study’s year is marked. 22 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 72 across 170 interventional studies indexed under Combat Disorders.
Median enrollment 74 across the 100 interventional studies, 111 across the 14 observational. Of the 61 that completed or were terminated, 21 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 114 have an industry lead sponsor. The 10 most frequent:
COMPASS Pathways is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
COMPASS Pathways has 1 study filed under Combat Disorders — fewer than ten, so there is no comparison to draw.
15 of the studies in Combat Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06228391Minneapolis Veterans Affairs Medical CenterKetamine Treatment for PTSD and MDD in TBI | 2026-12 |
| NCT07463703Cognitive FXAccelerated Transcranial Magnetic Stimulation for Post-Traumatic Stress Disorder | 2026-12 |
| NCT05414708Walter Reed National Military Medical CenterArt Therapy and Emotional Well Being in Military Populations With Posttraumatic Stress Symptoms | 2026-12 |
| NCT07523685Acacia ClinicsNon-invasive Vagus Nerve Stimulation (nVNS) for Post-Traumatic Stress Disorder (PTSD) | 2027-01 |
| NCT07336251White River Junction Veterans Affairs Medical CenterTranscranial Magnetic Stimulation in Veterans With PTSD | 2027-01 |
Add all 15 to your calendar (.ics) → With an account.
Among the 114 studies in Combat Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Diagnosed with certain psychiatric conditions such as bipolar disorder, schizophrenia, OCD, anorexia, or other conditions
Drug: COMP360 psilocybin
Drug: COMP360 psilocybin
Drug: COMP360 psilocybin
COMP360 psilocybin administered with monitoring and support
COMP360 25 mg versus COMP360 1 mg change from Baseline to Week 8 in CAPS-5 total severity score
The CAPS-5 (Clinician-Administered PTSD Scale for DSM-5) is a 30-item structured interview that yields a total severity score (0-80) reflecting PTSD symptoms. A higher CAPS-5 score indicates more severe, intense, and frequent PTSD symptoms.
Time frame: 8 weeks
Started Sep 2026 (actual). Primary completion is estimated for Nov 2028, 26 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin
COMPASS Pathways